Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Range of antinuclear antibodies in "healthy" individuals.
Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Tan EM, et al. Among authors: kalden jr. Arthritis Rheum. 1997 Sep;40(9):1601-11. doi: 10.1002/art.1780400909. Arthritis Rheum. 1997. PMID: 9324014
Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting.
Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, Lahita R, Maini RN, Reeves W, Reichlin M, Rothfield N, Takasaki Y, van Venrooij WJ, Tan EM. Smolen JS, et al. Among authors: kalden jr. Arthritis Rheum. 1997 Mar;40(3):413-8. doi: 10.1002/art.1780400304. Arthritis Rheum. 1997. PMID: 9082926
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity.
Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Rothfield NF, Smeenk R, Takasaki Y, van Venrooij WJ, Wiik A, Wilson M, Koziol JA. Tan EM, et al. Among authors: kalden jr. Arthritis Rheum. 1999 Mar;42(3):455-64. doi: 10.1002/1529-0131(199904)42:3<455::AID-ANR10>3.0.CO;2-3. Arthritis Rheum. 1999. PMID: 10088768 Free article.
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Maini RN, et al. Among authors: kalden jr. Arthritis Rheum. 1998 Sep;41(9):1552-63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. Arthritis Rheum. 1998. PMID: 9751087 Clinical Trial.
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories.
Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG, Slivka L, Koziol JA. Fritzler MJ, et al. Among authors: kalden jr. J Rheumatol. 2003 Nov;30(11):2374-81. J Rheumatol. 2003. PMID: 14677180
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE; ATTRACT Study Group. Smolen JS, et al. Among authors: kalden jr. Arthritis Rheum. 2005 Apr;52(4):1020-30. doi: 10.1002/art.20982. Arthritis Rheum. 2005. PMID: 15818697 Free article. Clinical Trial.
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Maini RN, et al. Among authors: kalden jr. Arthritis Rheum. 2004 Apr;50(4):1051-65. doi: 10.1002/art.20159. Arthritis Rheum. 2004. PMID: 15077287 Free article. Clinical Trial.
Preface.
Breedveld FC, Kalden JR, Smolen JS. Breedveld FC, et al. Among authors: kalden jr. Semin Arthritis Rheum. 2019 Dec;49(3S):S1-S2. doi: 10.1016/j.semarthrit.2019.10.004. Epub 2019 Oct 31. Semin Arthritis Rheum. 2019. PMID: 31706626 No abstract available.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. St Clair EW, et al. Among authors: kalden jr. Arthritis Rheum. 2004 Nov;50(11):3432-43. doi: 10.1002/art.20568. Arthritis Rheum. 2004. PMID: 15529377 Free article. Clinical Trial.
616 results